MedTrace Logo

PREVALENCE OF Anti-CCP POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS

NCT03267147 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 986

Last updated 2022-03-02

No results posted yet for this study

Summary

Non-interventional, prospective, observational study to assess the relative risk of anti-CCP positive patients to develop (subclinical) signs of inflammation in accordance with early Rheumatoid Arthritis (RA) in a population without pre-classified RA but new1 onset of non-specific musculoskeletal (MSK) symptoms in general practices in Germany and subsequent 36 months follow-up by rheumatologists

Conditions

Interventions

OTHER

no intervention is given

no intervention is given

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Goethe University

    collaborator OTHER

  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

    lead OTHER

Principal Investigators

  • Frank Behrens, MD · Fraunhofer IME

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-27
Primary Completion
2021-12-16
Completion
2022-02-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03267147 on ClinicalTrials.gov